Search - tctmd.com

Displaying 81 - 100 of 126

Sort: Relevancy | Date

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

October 23, 2019

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

News Conference News TCT 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

September 29, 2019

Off Script: Implicit Bias Can Be a Matter of Life and Death—Let’s Do Something About It

News Opinion Off Script

Off Script: Implicit Bias Can Be a Matter of Life and Death—Let’s Do Something About It

Quinn Capers IV, MD

September 23, 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

September 18, 2019

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

September 13, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

September 01, 2019

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

August 23, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

TCTMD’s Top 10 Most Popular Stories for July 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

July 31, 2019

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

News Daily News

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

March 21, 2019

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

News Daily News

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

March 04, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

TCTMD’s Top 10 Most Popular Stories for January 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

January 31, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.